297 related articles for article (PubMed ID: 23895680)
21. Betanin, isolated from fruits of Opuntia elatior Mill attenuates renal fibrosis in diabetic rats through regulating oxidative stress and TGF-β pathway.
Sutariya B; Saraf M
J Ethnopharmacol; 2017 Feb; 198():432-443. PubMed ID: 28111218
[TBL] [Abstract][Full Text] [Related]
22. Cellular basis of diabetic nephropathy: II. The transforming growth factor-beta system and diabetic nephropathy lesions in type 1 diabetes.
Huang C; Kim Y; Caramori ML; Fish AJ; Rich SS; Miller ME; Russell GB; Mauer M
Diabetes; 2002 Dec; 51(12):3577-81. PubMed ID: 12453917
[TBL] [Abstract][Full Text] [Related]
23. Diabetic nephropathy -- a multifaceted target of new therapies.
Choudhury D; Tuncel M; Levi M
Discov Med; 2010 Nov; 10(54):406-15. PubMed ID: 21122472
[TBL] [Abstract][Full Text] [Related]
24. Podocyte Autophagy: A Potential Therapeutic Target to Prevent the Progression of Diabetic Nephropathy.
Liu N; Xu L; Shi Y; Zhuang S
J Diabetes Res; 2017; 2017():3560238. PubMed ID: 28512641
[TBL] [Abstract][Full Text] [Related]
25. Rethinking glomerular basement membrane thickening in diabetic nephropathy: adaptive or pathogenic?
Marshall CB
Am J Physiol Renal Physiol; 2016 Nov; 311(5):F831-F843. PubMed ID: 27582102
[TBL] [Abstract][Full Text] [Related]
26. Diabetic retinopathy may predict the renal outcomes of patients with diabetic nephropathy.
Zhang J; Wang Y; Li L; Zhang R; Guo R; Li H; Han Q; Teng G; Liu F
Ren Fail; 2018 Nov; 40(1):243-251. PubMed ID: 29633887
[TBL] [Abstract][Full Text] [Related]
27. Role of VEGF-A and LRG1 in Abnormal Angiogenesis Associated With Diabetic Nephropathy.
Zhang A; Fang H; Chen J; He L; Chen Y
Front Physiol; 2020; 11():1064. PubMed ID: 32982792
[TBL] [Abstract][Full Text] [Related]
28. Signaling pathways in diabetic nephropathy.
Kawanami D; Matoba K; Utsunomiya K
Histol Histopathol; 2016 Oct; 31(10):1059-67. PubMed ID: 27094540
[TBL] [Abstract][Full Text] [Related]
29. Combination of telmisartan with sildenafil ameliorate progression of diabetic nephropathy in streptozotocin-induced diabetic model.
El-Mahdy NA; El-Sayad ME; El-Kadem AH
Biomed Pharmacother; 2016 Jul; 81():136-144. PubMed ID: 27261587
[TBL] [Abstract][Full Text] [Related]
30. Diabetic kidney lesions of GIPRdn transgenic mice: podocyte hypertrophy and thickening of the GBM precede glomerular hypertrophy and glomerulosclerosis.
Herbach N; Schairer I; Blutke A; Kautz S; Siebert A; Göke B; Wolf E; Wanke R
Am J Physiol Renal Physiol; 2009 Apr; 296(4):F819-29. PubMed ID: 19211686
[TBL] [Abstract][Full Text] [Related]
31. MicroRNA: A new generation therapeutic target in diabetic nephropathy.
Dewanjee S; Bhattacharjee N
Biochem Pharmacol; 2018 Sep; 155():32-47. PubMed ID: 29940170
[TBL] [Abstract][Full Text] [Related]
32. Transforming growth factor-β and Smads.
Lan HY; Chung ACK
Contrib Nephrol; 2011; 170():75-82. PubMed ID: 21659760
[TBL] [Abstract][Full Text] [Related]
33. Pyruvate kinase M2 activation may protect against the progression of diabetic glomerular pathology and mitochondrial dysfunction.
Qi W; Keenan HA; Li Q; Ishikado A; Kannt A; Sadowski T; Yorek MA; Wu IH; Lockhart S; Coppey LJ; Pfenninger A; Liew CW; Qiang G; Burkart AM; Hastings S; Pober D; Cahill C; Niewczas MA; Israelsen WJ; Tinsley L; Stillman IE; Amenta PS; Feener EP; Vander Heiden MG; Stanton RC; King GL
Nat Med; 2017 Jun; 23(6):753-762. PubMed ID: 28436957
[TBL] [Abstract][Full Text] [Related]
34. The analysis of risk factors for diabetic nephropathy progression and the construction of a prognostic database for chronic kidney diseases.
Wang G; Ouyang J; Li S; Wang H; Lian B; Liu Z; Xie L
J Transl Med; 2019 Aug; 17(1):264. PubMed ID: 31409386
[TBL] [Abstract][Full Text] [Related]
35. Protection of CTGF Antibody Against Diabetic Nephropathy in Mice Via Reducing Glomerular β-Catenin Expression and Podocyte Epithelial-Mesenchymal Transition.
Dai HY; Ma LN; Cao Y; Chen XL; Shi H; Fan YP; Yang B
J Cell Biochem; 2017 Nov; 118(11):3706-3712. PubMed ID: 28370212
[TBL] [Abstract][Full Text] [Related]
36. Interleukin-22 ameliorated renal injury and fibrosis in diabetic nephropathy through inhibition of NLRP3 inflammasome activation.
Wang S; Li Y; Fan J; Zhang X; Luan J; Bian Q; Ding T; Wang Y; Wang Z; Song P; Cui D; Mei X; Ju D
Cell Death Dis; 2017 Jul; 8(7):e2937. PubMed ID: 28726774
[TBL] [Abstract][Full Text] [Related]
37. The roles of sodium-glucose cotransporter 2 inhibitors in preventing kidney injury in diabetes.
Jaikumkao K; Pongchaidecha A; Chatsudthipong V; Chattipakorn SC; Chattipakorn N; Lungkaphin A
Biomed Pharmacother; 2017 Oct; 94():176-187. PubMed ID: 28759755
[TBL] [Abstract][Full Text] [Related]
38. miR-133b and miR-199b knockdown attenuate TGF-β1-induced epithelial to mesenchymal transition and renal fibrosis by targeting SIRT1 in diabetic nephropathy.
Sun Z; Ma Y; Chen F; Wang S; Chen B; Shi J
Eur J Pharmacol; 2018 Oct; 837():96-104. PubMed ID: 30125566
[TBL] [Abstract][Full Text] [Related]
39. Knockdown of Angiopoietin-Like Protein 2 Ameliorates Diabetic Nephropathy by Inhibiting TLR4.
Yang S; Zhang J; Wang S; Shi J; Zhao X
Cell Physiol Biochem; 2017; 43(2):685-696. PubMed ID: 28946139
[TBL] [Abstract][Full Text] [Related]
40. Preservation of renal function in chronic diabetes by enhancing glomerular glucose metabolism.
Qi W; Li Q; Gordin D; King GL
J Mol Med (Berl); 2018 May; 96(5):373-381. PubMed ID: 29574544
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
